This study involves the enrollment of two patient populations. For the neonatal population, we aim to develop a more accurate and efficient method for identifying abnormalities in the newborn brain using MRI imaging. MRI is the most advanced technique to examine the newborn brain, and it does not involve radiation unlike x-rays or CT. Participation will involve a 60-minute MRI scan without any sedation or contrast injections as well as approximately 2 hours dedicated to swaddling and feeding your child in preparation for the scan.
   

In PEPERONI (PlacEntal PERfusion and OxygeNation Imaging), we use cutting-edge imaging to monitor how well the placenta works. The placenta, a unique and vital organ, is shared by the mother and her offspring during pregnancy. In this study, we are using advanced magnetic resonance imaging (MRI) methods to assess how the placenta performs essential functions, such as perfusion (blood flow) and oxygenation.

This study is evaluating the addition of stereotactic radiosurgery (SRS) before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. 

This clinical trial is for men and women with locally advanced or metastatic solid tumor malignancies who have progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy.

The purpose of this study is to evaluate the safety and effectiveness of KB707. KB707 is experimental, which means that it is being tested and is not yet approved by the United States Food and Drug Administration (FDA).

This clinical trial is for men and women who have mantle cell lymphoma, a sub-type of B-cell non-Hodgkin lymphoma, who have never received treatment for their disease before.

The purpose of this study is to see if an experimental drug, called milvexian in addition to standard of care, is safe and useful in reducing the risk of future ischemic stroke in subjects after ischemic stroke or transient ischemic attack compared to placebo (tablet with no active drug) in addition to standard of care. This research is important to future patients, as this knowledge may help doctors do a better job of preventing stroke in patients.

Experimental means that milvexian has not yet been approved by the U.S. Food and Drug Administration (FDA). 

The purpose of this research study is to see whether ticagrelor and aspirin or rivaroxaban and aspirin compared to clopidogrel and aspirin may have the most success in preventing another stroke, bleed in the brain, or death in participants who have already had a stroke from a narrowed brain artery. This research is important to future patients, as this knowledge may help doctors do a better job of preventing stroke in patients with major narrowing of brain arteries.

The purpose of this study is to evaluate the safety and efficacy of OBP-301 with pembrolizumab in advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma (gastroesophageal adenocarcinoma).
   
OBP-301 is experimental, which means that it in combination with pembrolizumab is being tested and they are not yet approved by the United States Food and Drug Administration (FDA). 

This clinical trial is for adult participants who have primary antiphospholipid syndrome (APS). APS is a rare and chronic autoimmune disorder, meaning that it occurs when the body's immune system mistakenly attacks healthy tissues and organs. APS is common in patients with other autoimmune or rheumatic diseases, particularly systemic lupus erythematosus (SLE). APS is referred to as "primary" when it occurs alone. Participants in this study have been diagnosed with primary APS.
   

This clinical trial is for men and women who have high-risk large B-cell lymphoma (LBCL) and standard therapies available to treat their disease have limited effectiveness.